Search Within

Marissa Mattar

Formats
  1. Journal Article (31)
  2. Meeting Abstract (21)
  3. Book Section (3)
  4. Editorial (1)
  5. Research Letter (1)
Groups
  1. GSK Faculty (52)
  2. Sloan Kettering Institute Postdocs (48)
  3. Department of Pathology and Laboratory Medicine (44)
  4. Human Oncology and Pathogenesis Program (43)
  5. Department of Medicine (42)
  6. Tow Center for Developmental Oncology (TCDO) (40)

More Groups

People
  1. Elisa De Stanchina (44)
  2. Marc Ladanyi (32)
  3. Romel Somwar (31)
  4. Inna Khodos (27)
  5. Alexander Drilon (15)
  6. Charles Rudin (13)

More People

Years
  1. 2025 (1)
  2. 2024 (4)
  3. 2023 (3)
  4. 2022 (14)
  5. 2021 (11)
  6. 2020 (8)

More Years

Publications
  1. Cancer Research (6)
  2. Clinical Cancer Research (5)
  3. Journal of Thoracic Oncology (5)
  4. Cancer Discovery (4)
  5. Cancer Cell (3)
  6. Journal of Clinical Oncology (3)

More Publications

Publishers
  1. American Association for Cancer Research (16)
  2. Elsevier Inc. (8)
  3. Cell Press (6)
  4. American Society of Clinical Oncology (5)
  5. Academic Press, Elsevier Inc (3)
  6. Nature Publishing Group (3)

More Publishers

Results (57)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Complete pathological response to crizotinib in a patient with ALK-rearranged lung adenocarcinoma
    Journal Article

    Mattar, M. S.; Chang, J.; Benayed, R.; Halpenny, D.; Powers, A.; Kleiner, D. E.; Drilon, A.; Kris, M. G.
    Clinical Lung Cancer (2020)

    Fulltext@MSK | Save
  • Generation and characterization of patient-derived preclinical models from tumor cells isolated from cerebrospinal fluid
    Meeting Abstract

    Offin, M.; Vojnic, M.; Liu, Z.; Lui, A.; Siau, E.; Gladstone, E.; Mattar, M.; Khodos, I.; Drilon, A.; Boire, A.; more...
    Neuro-Oncology Advances (2019)

    Fulltext@MSK | Save
  • Generation and characterization of novel preclinical disease models of NSCLC with NRG1 rearrangements to improve therapy
    Meeting Abstract

    Gladstone, E.; Vojnic, M.; Offin, M.; Delasos, L.; Lui, A.; Siau, E.; Sato, H.; Benayed, R.; Kurth, R.; Mattar, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • Identification of neoantigens from non-primary tumor tissue in patients with recurrent ovarian cancer by sequencing and subsequent HLA ligand mass spectrometry
    Meeting Abstract

    O'Cearbhaill, R.; Klatt, M.; Mun, S. S.; Korontsvit, T.; Socci, N.; Guzman, S.; Mattar, M.; Zivanovic, O.; Dao, T.
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAP kinase pathway activation
    Meeting Abstract

    Cocco, E.; Kulick, A.; Misale, S.; Yaeger, R.; Razavi, P.; Won, H. H.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; Cownie, J.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Resistance to TRK inhibition mediated by convergent MAPK pathway activation
    Research Letter

    Cocco, E.; Schram, A. M.; Kulick, A.; Misale, S.; Won, H. H.; Yaeger, R.; Razavi, P.; Ptashkin, R.; Hechtman, J. F.; Toska, E.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer
    Journal Article

    Sanchez-Vega, F.; Hechtman, J. F.; Castel, P.; Ku, G. Y.; Tuvy, Y.; Won, H.; Fong, C. J.; Bouvier, N.; Nanjangud, G. J.; Soong, J.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer
    Journal Article

    Suzawa, K.; Offin, M.; Lu, D.; Kurzatkowski, C.; Vojnic, M.; Smith, R. S.; Sabari, J. K.; Tai, H.; Mattar, M.; Khodos, I.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Acquired BRAF fusions as a mechanism of resistance to EGFR therapy
    Meeting Abstract

    Vojnic, M.; Kurzatkowski, C.; Kubota, D.; Suzawa, K.; Liu, Z.; Mattar, M.; Khodos, I.; Poirier, J. T.; de Stanchina, E.; Rudin, C. M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Meeting Abstract

    Suzawa, K.; Offin, M. D.; Kurzatkowski, C.; Liu, D.; Vojnic, M.; Smith, R. S.; Mattar, M.; Khodos, I.; de Stanchina, E.; Sabari, J. K.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save